CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer.

Wolfgang Hilbe, Ufuk Abacioglu, Daniel M. Aebersold, Mounir Bachouchi, Thomas Brodowicz, Rabab Gaafar, Gerold Holzer, Andrea Mohn-Staudner, Dimitar Kalev, Ewa Kalinka-Warzocha, Viljem Kovac, Marco Siano, Fulden Yumuk, Lilla Tamasi

MEMO 1/13, 75-82

Experts opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Anghel R., Bachmann A., Beksac M. Brodowicz T., Finek J., Komadina R., Krzemieniecki K., Lang I., Marencak J., von Moos R., Pecherstorfer M., Rordorf T., Vrbanec D., Zielinski C.

Wiener Klinische Wochenschrift, 15-16/13, 439-447

Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the german study groups.

Untch M, Loibl S, Konecny GE, von Minckwitz G.

Curr Oncol Rep. 2012 Feb; 14(1):27-34

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Köstler WJ, Brodowicz T, Zielinski CC; Central European Cooperative Oncology Group (CECOG).

J Natl. Cancer Inst. 2010 Feb 3; 102(3): 207

The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.

Zielinski CC, Awada A, Cameron DA, Cufer T, Martin M, Aapro M.

Eur J Cancer. 2008 Feb; 44(3):353-65. Epub 2008 Jan 11. Review.

Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.

Zielinski CC.

Oncology (Williston Park) 2003 Dec; 17(12 Suppl 14):36-40. Review.

Cancer clinical trials in Central and Eastern Europe: historical review.

Jassem J, Schoket Z, Krzakowski M.

Crit Rev Oncol Hematol. 2002 May;42(2):157-61.

Prof. Zielinski on Publications

CECOG Contact Information

Please feel free to contact us if you have any questions.